Targeting IL-15 in large granular lymphocyte leukemia
- PMID: 23634735
- PMCID: PMC3889194
- DOI: 10.1586/eci.13.28
Targeting IL-15 in large granular lymphocyte leukemia
Abstract
IL-15 is a cytokine that stimulates the proliferation of NK and T cells. Previous studies have shown that IL-15 is critical to the induction of T-cell large granular lymphocyte (T-LGL) leukemia. A Phase I trial of a humanized antibody (Hu-Mikβ1) to the IL2/IL15Rβ receptor, expressed on T-LGL, is explored in this trial to evaluate the safety, pharmacokinetics, specificity and clinical efficacy of Hu-Mikβ1. The study demonstrated no toxicity and favorable saturation of IL2/IL15Rβ receptor, but no clinical efficacy in this Phase I study.
Comment on
-
Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemia.Blood. 2013 Jan 17;121(3):476-84. doi: 10.1182/blood-2012-08-450585. Epub 2012 Dec 3. Blood. 2013. PMID: 23212516 Free PMC article. Clinical Trial.
References
-
- Zhang D, Loughran TP., Jr Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment. Hematology Am Soc Hematol Educ Program. 2012;2012:652–659. - PubMed
-
- Epling-Burnette PK, Bai F, Wei S, et al. ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL) Oncogene. 2004;23(57):9220–9229. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources